Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Reckitt to sell E45 skincare brand for £200m

E45 cream was created in 1952 by Reckitt subsidiary Crookes Healthcare.

Henry Saker-Clark
Friday 24 December 2021 02:52 EST
Reckitt is selling skincare cream brand E45 for £200m (Reckitt/PA)
Reckitt is selling skincare cream brand E45 for £200m (Reckitt/PA)

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

Consumer giant Reckitt Benckiser has agreed the sale of skincare brand E45 for £200 million.

The Slough-based company, which also owns brand including Dettol and Durex told investors on Friday morning that it is set to sell the business to Swedish group Karo Pharma.

E45 cream was created in 1952 by Reckitt subsidiary Crookes Healthcare and was initially only available in hospitals.

However, increased demand and positive results saw the brand move into traditional retail.

In the financial year to December 2020, the E45 brand and related sub-brands had a combined net revenue of £43 million.

Now is the right time to pass E45 on to a new owner, and we are confident that Karo will build on the strength of the E45 brand to capture the significant opportunities ahead

Laxman Narasimhan, Reckitt Benckiser

The proposed sale is the latest move by Reckitt to shake up its portfolio in a bid to focus on higher growth areas of its operations.

It comes after the firm sold its infant formula and child nutrition business in China and its Scholl foot treatment brand earlier this year.

Reckitt’s strategy also saw it acquire menthol treatment business Biofreeze in July.

Chief executive Laxman Narasimhan aid: “E45 is an iconic, trusted skincare brand that over 60 years has become a leader in science-based skincare.

“As we shift from a brand-led to a category-led growth strategy, we are focusing on high growth categories with brands we can stretch into new places and spaces to support our medium-term growth ambitions, including 4%-6% growth in health.

“Now is the right time to pass E45 on to a new owner, and we are confident that Karo will build on the strength of the E45 brand to capture the significant opportunities ahead.”

The sale is subject to closing conditions, including consultations with employee representatives in France, but is expected to complete in the second quarter of next year.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in